Abstract
In 2025, the Trump administration disrupted many critical aspects of the biomedical research infrastructure in the United States. The Food and Drug Administration (FDA) was not spared. Robert F. Kennedy, Jr., a known vaccine denier with no health care experience, was confirmed as Secretary of the U.S. Department of Health and Human Services (HHS) in February 2025, followed by the confirmation of Dr. Martin Makary as Commissioner of the FDA in April. Departures of long-time FDA scientists, coupled with appointments of key personnel, seemingly because of their public stances on COVID-19 mRNA vaccines, have resulted in a tumultuous year for the agency. Though the FDA prior to the Trump administration was not without its flaws, actions by the current administration have generated unprecedented opposition. Unlike prior administrations, major policy changes have come without Congressional mandates. Opinion articles in major medical journals have largely supplanted notice and comment rulemaking. Indeed, twelve former FDA Commissioners assert that “If the goal is to rebuild confidence, the answer is not to toss aside the basic rules of science, stifle argument and oversight, or supplant expert scientific inquiry for the unilateral decision making of a few individuals.” The FDA is at a critical juncture. It could continue down this path, which might result in its ultimate destruction; or it could change course, rebuilding and fortifying the agency for generations to come. This Article speculates as to what the FDA may look like in 2050 under both best-and worst-case scenarios.